3SBio Valuation

Is 1530 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1530 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1530 (HK$6.81) is trading below our estimate of fair value (HK$18.09)

Significantly Below Fair Value: 1530 is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1530?

Other financial metrics that can be useful for relative valuation.

1530 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.8x
Enterprise Value/EBITDA6.3x
PEG Ratio0.6x

Price to Earnings Ratio vs Peers

How does 1530's PE Ratio compare to its peers?

The above table shows the PE ratio for 1530 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29x
6826 Shanghai Haohai Biological Technology
15.6x16.6%HK$15.8b
2696 Shanghai Henlius Biotech
16.2x11.5%HK$12.4b
6955 Shandong Boan Biotechnology
78.1xn/aHK$5.3b
1061 Essex Bio-Technology
6.3xn/aHK$1.6b
1530 3SBio
8.8x14.6%HK$16.0b

Price-To-Earnings vs Peers: 1530 is good value based on its Price-To-Earnings Ratio (8.8x) compared to the peer average (29x).


Price to Earnings Ratio vs Industry

How does 1530's PE Ratio compare vs other companies in the Asian Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a39.7%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a39.7%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 1530 is good value based on its Price-To-Earnings Ratio (8.8x) compared to the Asian Biotechs industry average (31.1x).


Price to Earnings Ratio vs Fair Ratio

What is 1530's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1530 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio8.8x
Fair PE Ratio13.6x

Price-To-Earnings vs Fair Ratio: 1530 is good value based on its Price-To-Earnings Ratio (8.8x) compared to the estimated Fair Price-To-Earnings Ratio (13.6x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1530 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$6.81
HK$8.04
+18.0%
16.0%HK$10.08HK$6.25n/a9
Oct ’25HK$6.87
HK$8.04
+17.0%
16.0%HK$10.08HK$6.25n/a9
Sep ’25HK$6.06
HK$8.04
+32.6%
16.0%HK$10.08HK$6.25n/a9
Aug ’25HK$6.04
HK$7.56
+25.2%
17.7%HK$9.98HK$6.15n/a7
Jul ’25HK$6.44
HK$7.49
+16.3%
17.9%HK$10.00HK$6.14n/a7
Jun ’25HK$6.10
HK$7.46
+22.2%
16.5%HK$9.59HK$6.17n/a7
May ’25HK$6.28
HK$7.46
+18.7%
16.5%HK$9.59HK$6.17n/a7
Apr ’25HK$5.98
HK$7.53
+25.9%
16.4%HK$9.60HK$6.17n/a7
Mar ’25HK$5.62
HK$8.19
+45.7%
13.0%HK$9.70HK$6.30n/a7
Feb ’25HK$6.02
HK$8.67
+44.0%
8.5%HK$9.80HK$7.71n/a7
Jan ’25HK$7.52
HK$8.67
+15.3%
8.5%HK$9.80HK$7.71n/a7
Dec ’24HK$7.51
HK$8.47
+12.8%
8.2%HK$9.52HK$7.65n/a7
Nov ’24HK$6.95
HK$8.47
+21.9%
8.2%HK$9.52HK$7.65n/a7
Oct ’24HK$6.55
HK$8.30
+26.7%
9.9%HK$9.55HK$6.98HK$6.878
Sep ’24HK$6.56
HK$8.25
+25.7%
9.9%HK$9.60HK$7.02HK$6.069
Aug ’24HK$7.22
HK$8.53
+18.2%
11.9%HK$10.68HK$7.10HK$6.049
Jul ’24HK$7.87
HK$8.45
+7.4%
12.0%HK$10.69HK$7.11HK$6.449
Jun ’24HK$7.77
HK$8.76
+12.8%
12.0%HK$11.13HK$7.40HK$6.109
May ’24HK$7.85
HK$8.75
+11.5%
12.0%HK$11.11HK$7.39HK$6.289
Apr ’24HK$7.82
HK$8.70
+11.2%
11.5%HK$11.19HK$7.44HK$5.9811
Mar ’24HK$8.03
HK$7.91
-1.5%
16.8%HK$10.86HK$5.89HK$5.6211
Feb ’24HK$8.58
HK$7.95
-7.4%
16.6%HK$11.00HK$5.97HK$6.0211
Jan ’24HK$8.30
HK$7.27
-12.4%
19.4%HK$10.80HK$5.50HK$7.5210
Dec ’23HK$8.27
HK$7.06
-14.6%
19.8%HK$10.52HK$5.29HK$7.5110
Nov ’23HK$5.80
HK$6.88
+18.7%
20.4%HK$10.50HK$5.28HK$6.9510
Oct ’23HK$5.57
HK$6.86
+23.2%
20.5%HK$10.50HK$5.28HK$6.5510

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies